JAC Advance Access originally published online on May 23, 2005
Journal of Antimicrobial Chemotherapy 2005 56(1):180-185; doi:10.1093/jac/dki148
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Linezolid for the treatment of multidrug-resistant tuberculosis
1 Infectious Diseases Department, Ramón y Cajal Hospital, Madrid, Spain; 2 Microbiology Department, Ramón y Cajal Hospital, Madrid, Spain
Received 24 January 2005; returned 22 February 2005; revised 18 March 2005; accepted 2 April 2005
*Corresponding author. Email: fortun{at}mi.madritel.es or fortun.hrc{at}salud.madrid.org
Objectives: In vitro studies have shown good activity of linezolid against Mycobacterium tuberculosis, including multidrug-resistant strains. However, clinical experience with linezolid in tuberculosis is scarce.
Methods: We report our clinical experience with five consecutive patients with multidrug-resistant tuberculosis infection treated with combination regimens that included linezolid.
Results: Two patients had multidrug-resistant Mycobacterium bovis infection, with resistance to 12 antituberculous agents (one of them with HIV co-infection and <50 CD4 cells/mm3). The other three patients were infected by multidrug-resistant M. tuberculosis strains, with resistance to all first-line drugs and other second-line drugs. All patients received linezolid in combination with thiacetazone, clofazimine or amoxicillin/clavulanate. Susceptibility tests showed linezolid MIC values 
0.5 mg/L against all tuberculosis strains tested (standard proportion method, Middlebrook agar 7H10). In all cases, tuberculosis cultures from respiratory samples were sterile after 6 weeks of therapy. Three patients have clinical and microbiological cure of tuberculosis with a combination regimen with linezolid (range: 5–24 months). One patient was lost to follow-up at month 5. The remaining patient has completed 11 months of therapy and is still on treatment. Four patients developed anaemia and needed blood transfusions. In two of these patients, the linezolid daily-dose (600 mg twice a day) was successfully reduced to 50% (300 mg twice a day) to decrease toxicity while maintaining efficacy. Peripheral neuropathy (two patients) and pancreatitis (one patient) were other adverse events observed during linezolid treatment.
Conclusions: In our experience, linezolid has been a valid alternative drug in the management of multidrug-resistant tuberculosis. The prolonged use of linezolid is frequently associated with toxicity, mainly anaemia and peripheral neuropathy, that requires special management.
Keywords: oxazolidinones , Mycobacterium tuberculosis , Mycobacterium bovis , MDR-TB
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Condos, N. Hadgiangelis, E. Leibert, G. Jacquette, T. Harkin, and W. N. Rom Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis Chest, July 1, 2008; 134(1): 187 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hillemann, S. Rusch-Gerdes, and E. Richter In Vitro-Selected Linezolid-Resistant Mycobacterium tuberculosis Mutants Antimicrob. Agents Chemother., February 1, 2008; 52(2): 800 - 801. [Full Text] [PDF]
|
|
|
|
|
|
L. Vera-Cabrera, B. A. Brown-Elliott, R. J. Wallace Jr., J. Ocampo-Candiani, O. Welsh, S. H. Choi, and C. A. Molina-Torres In Vitro Activities of the Novel Oxazolidinones DA-7867 and DA-7157 against Rapidly and Slowly Growing Mycobacteria Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4027 - 4029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Vera-Cabrera, E. Gonzalez, A. Rendon, J. Ocampo-Candiani, O. Welsh, V. M. Velazquez-Moreno, S. Hak Choi, and C. Molina-Torres In Vitro Activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3170 - 3172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I-N. Park, S.-B. Hong, Y.-M. Oh, M.-N. Kim, C.-M. Lim, S. D. Lee, Y. Koh, W. S. Kim, D. S. Kim, W. D. Kim, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis J. Antimicrob. Chemother., September 1, 2006; 58(3): 701 - 704. [Abstract] [Full Text] [PDF]
|
|